The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy
Multiple sclerosis (MS) is a highly heterogeneous disease involving a combination of inflammation, demyelination, and CNS injury.It is the leading cause of non-traumatic neurological disability in younger people.There is no cure, but treatments in the form of immunomodulatory drugs (IMDs) are available.Experience over the last 30 years has shown th